Outcomes in Older Patients with Newly Diagnosed High-Risk/Secondary AML (sAML) who Achieve Remission with CPX-351 versus 7+3 Induction

被引：0
|
作者：
Faderl, S. [1 ]
Uy, G. L. [2 ]
Schiller, G. J. [3 ]
Cortes, J. E. [4 ]
Ritchie, E. K. [5 ]
Ryan, R. J. [1 ]
Chiarella, M. [1 ]
Louie, A. C. [1 ]
机构：
[1] Jazz Pharmaceut, Palo Alto, CA USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA
来源：
ANNALS OF HEMATOLOGY | 2019年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
39
引用
收藏
页码：S39 / S40
页数：2
相关论文
共 50 条
  • [1] Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML
    Uy, Geoffrey L.
    Newell, Laura F.
    Lin, Tara L.
    Goldberg, Stuart L.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Lancet, Jeffrey E.
    BLOOD ADVANCES, 2022, 6 (17) : 4989 - 4993
  • [2] Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study
    Faderl, Stefan
    Cortes, Jorge E.
    Ritchie, Ellen K.
    Ryan, Robert J.
    Chiarella, Michael
    Schiller, Gary J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S206 - S207
  • [3] Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).
    Lin, Tara L.
    Medeiros, Bruno C.
    Uy, Geoffrey L.
    Newell, Laura Fugal
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen Anthony
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur Chin
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML)
    Lin, Tara L.
    Cortes, Jorge E.
    Newell, Laura F.
    Ritchie, Ellen K.
    Hogge, Donna E.
    Solomon, Scott R.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Ryan, Robert J.
    Louie, Arthur C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [5] Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.
    Lin, Tara L.
    Ryan, Robert J.
    Faderl, Stefan
    Ritchie, Ellen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).
    Ritchie, Ellen K.
    Lin, Tara L.
    Newell, Laura F.
    Stuart, Robert K.
    Solomon, Scott R.
    Stone, Richard M.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Ryan, Robert J.
    Chiarella, Michael
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
    Lin, Tara L.
    Rizzieri, David A.
    Ryan, Daniel H.
    Schiller, Gary J.
    Kolitz, Jonathan E.
    Uy, Geoffrey L.
    Hogge, Donna E.
    Solomon, Scott R.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    Lancet, Jeffrey E.
    BLOOD ADVANCES, 2021, 5 (06) : 1719 - 1728
  • [8] Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.
    Lancet, Jeffrey E.
    Uy, Geoffrey L.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen Anthony
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Ryan, Daniel H.
    Hoering, Antje
    Chiarella, Michael
    Louie, Arthur Chin
    Medeiros, Bruno C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML
    Lin, Tara L.
    Cortes, Jorge E.
    Newell, Laura F.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen A.
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Ryan, Robert
    Chiarella, Michael
    Louie, Arthur C.
    Uy, Geoffrey L.
    BLOOD, 2018, 132
  • [10] Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin
    Kolitz, Jonathan
    Strickland, Stephen A.
    Cortes, Jorge E.
    Hogge, Donna
    Lancet, Jeffrey E.
    Goldberg, Stuart
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur C.
    Uy, Geoffrey L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S208 - S209
12345